Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 294

1.

Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.

Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T.

J Immunol. 2003 Apr 15;170(8):4196-200.

2.

Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.

Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D.

J Exp Med. 2003 Jun 2;197(11):1427-39.

3.

Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.

Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman D, Kärre K, Cerboni C.

J Immunol. 2003 Jul 15;171(2):902-8.

4.

Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains.

Spreu J, Stehle T, Steinle A.

J Immunol. 2006 Sep 1;177(5):3143-9.

5.

Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.

Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG, Steinle A.

Eur J Immunol. 2003 Jan;33(1):194-203.

6.

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.

Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ.

Immunity. 2001 Feb;14(2):123-33.

7.

The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.

Sutherland CL, Chalupny NJ, Cosman D.

Immunol Rev. 2001 Jun;181:185-92. Review.

PMID:
11513139
8.

Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.

Müller S, Zocher G, Steinle A, Stehle T.

PLoS Pathog. 2010 Jan 15;6(1):e1000723. doi: 10.1371/journal.ppat.1000723.

9.

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.

Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D.

J Immunol. 2002 Jan 15;168(2):671-9.

10.

Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.

Chalupny NJ, Rein-Weston A, Dosch S, Cosman D.

Biochem Biophys Res Commun. 2006 Jul 21;346(1):175-81. Epub 2006 May 24.

PMID:
16750166
11.

NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145.

Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak-Pugel E, Messerle M, Hengel H, Busch DH, Koszinowski UH, Jonjic S.

J Exp Med. 2005 Jan 17;201(2):211-20. Epub 2005 Jan 10.

12.

The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope.

Valés-Gómez M, Winterhalter A, Roda-Navarro P, Zimmermann A, Boyle L, Hengel H, Brooks A, Reyburn HT.

Cell Microbiol. 2006 Apr;8(4):581-90.

PMID:
16548884
13.
14.

Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.

Wiemann K, Mittrücker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A.

J Immunol. 2005 Jul 15;175(2):720-9.

15.

Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.

Matusali G, Tchidjou HK, Pontrelli G, Bernardi S, D'Ettorre G, Vullo V, Buonomini AR, Andreoni M, Santoni A, Cerboni C, Doria M.

FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8.

PMID:
23395909
16.

Allelic MHC class I chain related B (MICB) molecules affect the binding to the human cytomegalovirus (HCMV) unique long 16 (UL16) protein: implications for immune surveillance.

Klumkrathok K, Jumnainsong A, Leelayuwat C.

J Microbiol. 2013 Apr;51(2):241-6. doi: 10.1007/s12275-013-2514-1. Epub 2013 Apr 27.

PMID:
23625227
17.

Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.

Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, Spies T.

Immunogenetics. 2001 May-Jun;53(4):279-87.

PMID:
11491531
18.

Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.

Song H, Kim J, Cosman D, Choi I.

Cell Immunol. 2006 Jan;239(1):22-30. Epub 2006 Apr 21.

PMID:
16630603
19.

Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.

Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A.

Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098.

20.

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S.

Blood. 2005 Jan 1;105(1):251-8. Epub 2004 Aug 24.

Supplemental Content

Support Center